Image Analysis Group (IAG) to Join High-Profile Pharma Services Panel at HBI 2026 in Paris
Dr. Olga Kubassova, CEO of IAG, will participate in the landmark “Maintaining Scalability and Differentiation in a Consolidating and Tech-Driven Market” panel at HBI 2026 –
Bringing the voice of an imaging technology innovator to Europe’s premier healthcare investing conference.
LONDON, UK — Image Analysis Group (IAG), the market-leading imaging contract research organisation (CRO) and the developer of the proprietary DYNAMIKA™ AI-enabled imaging platform, today announced that Dr. Olga Kubassova, Chief Executive Officer, will join the pharma services panel at the Healthcare Business International (HBI) 2026 conference, taking place 23–25 March 2026 at CNIT Forest, Paris, France. The panel, titled “Maintaining Scalability and Differentiation in a Consolidating and Tech-Driven Market,” will convene senior executives and investors from across the pharma services ecosystem for a high-level strategic debate on market momentum, artificial intelligence, competitive differentiation, and scalability in one of healthcare’s most dynamic service segments.
A Market-Defining Conversation at the Right Moment
HBI 2026 is Europe’s foremost CEO-level conference dedicated exclusively to healthcare investing and strategy, bringing together operators, investors, and innovators from across the global healthcare sector. The pharma services panel sits at the intersection of commercial strategy and scientific execution -precisely the domain in which IAG has established itself as a category leader over nearly two decades.
Against a backdrop of recovering biotech funding, evolving regulatory landscapes, and accelerating AI adoption across the clinical development value chain, this panel discussion could not be more timely. Dr. Kubassova will bring IAG’s unique dual perspective, that of a highly specialized, technology-first imaging CRO that is simultaneously a software and platform developer – to a conversation that typically features more broadly diversified CRO and CDMO businesses.
“The pharma services sector is at an inflection point. Consolidation is accelerating, adoption of technology, AI and exploratory endpoints are reshaping every corner of drug development. Sponsors are under greater pressure than ever to select partners who can deliver not just services — but answers. IAG was built specifically to meet that challenge, combining deep imaging science, global operational leadership with proprietary technology.” – Dr. Olga Kubassova, CEO, Image Analysis Group (IAG)
IAG: Technology Leadership Rooted in DYNAMIKA™
What sets IAG apart in the imaging CRO market is straightforward: IAG does not simply use technology –IAG builds it. The company’s proprietary DYNAMIKA™ platform is a purpose-built, AI-enabled imaging ecosystem that manages the entire clinical imaging lifecycle, from site image capture and secure cloud transfer to de-identification, quality control, centralized radiological review, and regulatory-grade endpoint generation. Unlike off-the-shelf imaging software deployed by competitors, DYNAMIKA™ is continuously developed and enhanced in-house by IAG’s scientific and engineering teams, ensuring that the platform evolves in direct response to sponsor needs, regulatory requirements, and the latest advances in medical image analysis.
DYNAMIKA™ delivers capabilities that translate directly into competitive advantage for pharma and biotech sponsors:
- Real-time imaging data dashboards providing instant visibility into site performance and data quality across global trials
- AI-powered image QC and anonymization reducing manual burden, minimizing errors, and accelerating study timelines
- Configurable eCRF-embedded workflows supporting complex read paradigms (single read, dual read, adjudication) across all modalities — MRI, CT, PET, DXA, X-ray, ultrasound
- Validated, regulatory-compliant imaging endpoints (RECIST, mRECIST, RANO, RAMRIS, and many more) with full audit trail to meet FDA 21 CFR Part 11, ICH E6, GDPR, HIPAA, ISO 13485, and SOC 2 Type II standards
- Advanced quantitative imaging and radiomics analytics enabling biomarker discovery and precision medicine endpoints
- Seamless integration with major eClinical platforms (EDC, eTMF, CTMS), reducing operational friction across the trial ecosystem
This technology ownership model is IAG’s core strategic moat. In an era where AI is becoming table stakes across the pharma services industry, IAG’s ability to develop, iterate, and deploy its own AI tools — rather than licensing generic solutions – creates a depth of scientific customization that generic CROs simply cannot replicate.
Nearly Two Decades of Imaging Excellence Across Global Trials
Founded in 2007, IAG has supported over 700 global clinical trials across a broad range of therapeutic areas including oncology, musculoskeletal and autoimmune disease, rare diseases, neurology, obesity/metabolic conditions, and paediatric indications. The company’s global footprint spans the United Kingdom (headquarters), the United States, Europe, Asia-Pacific.
IAG’s end-to-end capabilities encompass the full spectrum of imaging CRO services: protocol design and imaging charter development, site selection and activation, global site training and support, centralised data management and image QC, expert radiological review by world-class KOLs, advanced AI-enabled quantitative analysis, and regulatory submission support. For sponsors, this translates into a single, accountable imaging partner that reduces sample sizes, accelerates study timelines, and delivers regulator-ready imaging data with confidence.
Panel Themes: Where IAG’s Expertise Meets Investor Priorities
The HBI 2026 pharma services panel will address four critical themes shaping the future of the sector: market momentum, the impact of AI, differentiation, and scalability. Each of these themes maps directly onto IAG’s strategic narrative and real-world achievements:
- Market Momentum: As biotech funding recovers and large pharma resumes clinical pipeline investment following a period of uncertainty, demand for high-quality, tech-enabled imaging CRO services is accelerating. IAG is well-positioned to capture this momentum with a validated platform, an experienced team, and a robust commercial pipeline.
- Artificial Intelligence: Unlike competitors who are retrofitting AI into legacy workflows, IAG has been an AI-first organisation since inception. DYNAMIKA™’s AI capabilities — spanning automated QC, anonymisation, and quantitative endpoint analysis — are production-grade, regulatory-compliant, and sponsor-validated across hundreds of global trials.
- Differentiation: In a consolidating market where undifferentiated service providers face pricing pressure and margin compression, IAG’s ownership of DYNAMIKA™ creates a durable, defensible competitive position. Proprietary technology, combined with unparalleled therapeutic expertise, ensures IAG competes on value rather than price.
- Scalability: IAG’s cloud-native DYNAMIKA™ infrastructure is architected for global scale, supporting multi-site, multi-country, and multi-modal trials simultaneously. The platform’s configurable workflows and role-based access model mean that IAG can onboard new trials in weeks — not months — while maintaining the quality standards that regulators expect.hips.
An Ambitious Growth Trajectory – and an Open Invitation to Connect
The company is at an exciting inflection point in its growth journey, actively exploring strategic partnerships, investment opportunities, and collaborative ventures that will accelerate its mission to set the global standard for imaging in clinical trials.
HBI 2026 is the ideal forum for this. With Europe’s top healthcare investors, private equity firms, strategic acquirers, and pharma services executives all in one place, the conference represents a concentrated opportunity to connect with the right funding partners, co-development allies, and commercial collaborators who share IAG’s vision of a world in which imaging technology accelerates drug development and improves patient outcomes.
For pharma and biotech executives evaluating imaging CRO partners for upcoming trials, and for investors seeking high-conviction opportunities in the pharma services and healthtech convergence space, meeting with Dr. Kubassova at HBI 2026 is a conversation not to be missed.
“IAG has spent nearly two decades building the scientific and technological foundation that the market is now demanding. The time is right to scale, to partner, and to grow.” – Jonathan Shaul, CFO, Image Analysis Group (IAG)
Meet IAG at HBI 2026
Pharma, biotech, and investment professionals attending HBI 2026 are warmly invited to request a meeting with Dr. Olga Kubassova and the IAG team. Whether you are designing an upcoming clinical trial and seeking the most advanced imaging solution available, or you are an investor or strategic partner looking to understand IAG’s technology platform and growth strategy, our team is ready to engage.
Schedule a meeting: www.ia-grp.com/contact
Learn more about DYNAMIKA™
About Image Analysis Group (IAG)
Image Analysis Group (IAG) is the market-leading specialist imaging CRO, providing end-to-end imaging services and proprietary AI-enabled technology for clinical trials across all phases and therapeutic areas. Since its founding in 2007, IAG has supported over 700 global clinical trials, partnering with pharma, biotech, and medical device sponsors to deliver faster, more accurate, and regulatory-compliant imaging endpoints. IAG’s proprietary DYNAMIKA™ platform powers the company’s industry-leading imaging data management, AI-driven analysis, and real-time trial oversight capabilities. Headquartered in London, UK, IAG operates globally across the United States, Europe, Asia-Pacific, Latin America, and Africa. For more information, visit www.ia-grp.com.
About HBI 2026
The Healthcare Business International (HBI) conference is the premier CEO-level event dedicated to healthcare investing and strategy. HBI 2026 takes place 23–25 March 2026 at CNIT Forest, Paris, France, bringing together leading healthcare operators, investors, and innovators for deal-making, strategic alignment, and partnership building across the global healthcare sector.
